AMBITION
Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension
Doente / População Intervenção / Exposição Comparação Desfecho
In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.
N
500
Desenho
Double-blind RCT
Desfecho
First clinical-failure event
Relevância
1
ResultadoHR 0.50 for the primary composite.
Galiè N, et al. N Engl J Med. 2015;373(9):834-844. 10.1056/NEJMoa1413687
Discussão e crítica
Established upfront dual combination therapy as the standard initial approach for most patients with PAH.